FSTL3 and metabolic dysfunction-associated steatotic liver disease: Immunohistochemical staining of FSTL3 was also performed on liver biopsy specimens from 30 NAFLD patients with significant and advanced fibrosis (F2 and F3) and 30 NAFLD patients with fibrosis stage F0 and F1 (Fig. 2B, C).